These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 30341487)

  • 1. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system.
    Sessa M; Bernardi FF; Vitale A; Schiavone B; Gritti G; Mascolo A; Bertini M; Scavone C; Sportiello L; Rossi F; Capuano A
    J Clin Pharm Ther; 2018 Dec; 43(6):867-876. PubMed ID: 30014479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia.
    Dormuth CR; Fisher A; Carney G
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):796-802. PubMed ID: 31914214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project.
    Trifirò G; Isgrò V; Ingrasciotta Y; Ientile V; L'Abbate L; Foti SS; Belleudi V; Poggi F; Fontana A; Moretti U; Lora R; Sabaini A; Senesi I; Sorrentino C; Puzo MR; Padula A; Fusco M; Giordana R; Solfrini V; Puccini A; Rossi P; Del Zotto S; Leoni O; Zanforlini M; Ancona D; Bavaro V; Garau D; Ledda S; Scondotto S; Allotta A; Tuccori M; Gini R; Bucaneve G; Franchini D; Cavazzana A; Biasi V; Spila Alegiani S; Massari M;
    BioDrugs; 2021 Nov; 35(6):749-764. PubMed ID: 34637126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of biological medicines as compared with non-biologicals: an analysis of the italian spontaneous reporting system database.
    Cutroneo PM; Isgrò V; Russo A; Ientile V; Sottosanti L; Pimpinella G; Conforti A; Moretti U; Caputi AP; Trifirò G
    Drug Saf; 2014 Nov; 37(11):961-70. PubMed ID: 25255847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.
    di Mauro G; Zinzi A; Scavone C; Mascolo A; Gaio M; Sportiello L; Ferrajolo C; Rafaniello C; Rossi F; Capuano A
    Drug Saf; 2021 Mar; 44(3):337-349. PubMed ID: 33351170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register.
    Wallerstedt SM; Brunlöf G; Sundström A
    Drug Saf; 2011 Aug; 34(8):669-82. PubMed ID: 21751827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.
    Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M
    Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Rapid Infliximab Biosimilar Infusions in Patients With Inflammatory Bowel Disease.
    Kim JY; Bhat S
    Ann Pharmacother; 2022 Mar; 56(3):280-284. PubMed ID: 34192881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Campania Preventability Assessment Committee (Italy): A Focus on the Preventability of Non-steroidal Anti-inflammatory Drugs' Adverse Drug Reactions.
    Sessa M; Sportiello L; Mascolo A; Scavone C; Gallipoli S; di Mauro G; Cimmaruta D; Rafaniello C; Capuano A
    Front Pharmacol; 2017; 8():305. PubMed ID: 28603499
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database.
    Pugi A; Bonaiuti R; Maggini V; Moschini M; Tuccori M; Leone R; Rossi M; Motola D; Piccinni C; Ferrazin F; Sottosanti L; Mugelli A; Vannacci A; Lapi F
    Am J Health Syst Pharm; 2013 Jun; 70(12):1039-46. PubMed ID: 23719881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Int J Rheum Dis; 2018 May; 21(5):922-929. PubMed ID: 29671942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
    Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.